| The information set forth in Item 3 is incorporated herein by reference. Pursuant to the terms of the Plan, the Reporting Person received shares of Common Stock as reported in Item 3. These shares were acquired for investment purposes. On October 12, 2023, the Issuer entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the CWI Clients and certain other investors setting forth the terms by which the Issuer agreed to file with the SEC a resale shelf registration statement with respect to the shares of Common Stock owned by the parties thereto. The Registration Rights Agreement also provides for certain demand rights for underwritten offerings and other customary terms, including piggyback registration rights, conditions, and other provisions. The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement, which is filed hereto as Exhibit 99.1 and is incorporated by reference herein. On October 12, 2023, the Issuer entered into a Stockholders Agreement (the “Stockholders Agreement”) with the CWI Clients and other stockholders of the Issuer (the “Stockholders”) pursuant to which each of the Stockholders agreed to certain restrictions on the transfer of the shares of Common Stock and to vote their shares of Common Stock in favor of certain director designees. Additionally, under the Stockholders Agreement, the Issuer agreed to (i) certain limitations and obligations on its operations without Stockholder approval and (ii) provide certain information to the Stockholders. In addition, pursuant to the Stockholders Agreement, (x) CWI is entitled to designate one individual for appointment to the Issuer’s board of directors while the CWI Clients hold 15% or more of the fully diluted shares of Common Stock held by the Stockholders, and (y) CWI and one of the other Stockholders have the right to jointly designate an additional individual for appointment to the Issuer’s board of directors, but following the initial term of such director, CWI has agreed to permanently waive its designation right with respect to such director while such other Stockholder will continue to have the right to designate such director, subject to certain limitations. CWI also intends to waive its designation right going forward with respect to the director described in clause (x) above. The individuals designated pursuant to these rights were appointed effective as of October 12, 2023. Neither of the individuals designated pursuant to these rights are affiliated with the Reporting Person or any other CWI Client. The Stockholders Agreement also provides for certain preemptive, first refusal, tag-along, and drag-along rights. Pursuant to the Plan, each holder of Common Stock on the Effective Date was deemed to be a party to, and bound by, the Stockholders Agreement, regardless of whether such holder executed a signature page thereto. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that the Reporting Person or any of its affiliates (i) constitute a “group” for purposes of Section 13(d) or 13(g) of the Exchange Act with the other Stockholders and the Reporting Person expressly disclaims membership in any such group, or (ii) are the beneficial owners of any shares of Common Stock beneficially owned by the other Stockholders for purposes of Section 13(d) of the Exchange Act or for any other purpose. The foregoing description of the Stockholders Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Stockholders Agreement, which is filed hereto as Exhibit 99.2 and is incorporated by reference herein. The Reporting Person intends to evaluate on an ongoing basis its investment in the Issuer and its options with respect to such investment. Depending on market conditions, an evaluation of the business and the prospects of the Issuer and other factors, the Reporting Person may, in its sole discretion, purchase additional shares of Common Stock, or other securities convertible into or exchangeable for shares of Common Stock, and/or other equity, debt, notes, instruments or other securities of the Issuer, dispose of shares of Common Stock or such other securities from time to time in the open market, in privately negotiated transactions or otherwise, and/or otherwise change its intention with respect to any and all matters referred to in this Item 4. Except as set forth herein, the Reporting Person does not have, as of the date of this filing any plans or proposals that relate to or would result in any of the actions or events specified in clauses (a) through (j) of Item 4 of Schedule 13D. However, the Reporting Person reserves the right to adopt such plans or proposals in the future, subject to applicable regulatory requirements, if any. |